MY ACCOUNT | NEWSLETTER |

Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs


Pimobendan might have favorable effects on renal function, but this has not been well-studied in dogs with myxomatous mitral valve disease (MMVD). The aim of the study was to determine the effects of standard-dose (SD_pimo) and high-dose pimobendan (HD_pimo) on glomerular filtration rate (GFR) and cardiac size and function in dogs with preclinical MMVD.  

Thirty nonazotemic dogs with stage B2 MMVD was enrolled in this prospective, randomized, double-blinded, placebo-controlled clinical study. Dogs had an echocardiographic examination, assessment of GFR (iohexol clearance), N-terminal probrain natriuretic peptide (NT-proBNP), and quality of life (QOL) score at baseline and 7 to 10 days after placebo (n = 6), SD_pimo 0.2 to 0.3 mg/kg q12 (n = 12), or HD_pimo 0.5 to 0.6 mg/kg q12h (n = 12).  

Data showed that no significant differences in GFR or QOL scores were detected between groups (P ≥ .07). After HD_pimo, the mean [SD] percent change of NT_proBNP (-46.1 [20.2]%), left atrial volume (LAV; -27.1 [16.9]%), left ventricular end-diastolic volume (EDV; -21.8 [15.0]%), and end-systolic volume (ESV; -55.0 [20.7]%) were significantly different (P ≤ .004) from placebo (0.5 [19.9]%, 1.3 [15.6]%, -0.2 [8.2]%, -7.3 [35.6]%, respectively) but not the percent change after SD_pimo (-36.6 [16.1]%, -22.7 [14.9]%, -16.7 [12.5]%, -41.6 [14.8]%, respectively; P > .05). After SD_pimo, percent change of NTproBNP, LAV, EDV, and ESV were significantly different from placebo (P < .05).  

The authors said results suggest that pimobendan might not affect renal function in nonazotemic dogs with stage B2 MMVD. High dose pimobendan did not demonstrate advantages over SD_pimo within the constraints of the study.

Joanna L Kaplan, et al. “Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.” J Vet Intern Med. 2022 Sep 13. doi: 10.1111/jvim.16537

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Sploot opens second clinic in Denver, with more on the way

Like0
Dislike0

Dr. Christopher Byers: The pandemic broke me

Like0
Dislike0

Disaster preparedness for animals

Like0
Dislike0

Echocardiographic indicators of fluid responsiveness in hospitalized dogs with compromised hemodynamics, tissue hypoperfusion

Like0
Dislike0

Morris Animal Foundation accepting RFPs to use golden retriever study data, samples

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2022 - All Rights Reserved
ISSN 2768-198X

Top